Dakota Wealth Management Has $3.27 Million Position in Labcorp Holdings Inc. $LH

Dakota Wealth Management grew its stake in Labcorp Holdings Inc. (NYSE:LH) by 26.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,022 shares of the medical research company’s stock after acquiring an additional 2,719 shares during the quarter. Dakota Wealth Management’s holdings in Labcorp were worth $3,267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Caldwell Trust Co bought a new stake in Labcorp in the second quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new position in shares of Labcorp during the third quarter worth $28,000. Motco acquired a new position in shares of Labcorp in the 3rd quarter valued at $32,000. Beacon Financial Strategies CORP bought a new stake in shares of Labcorp in the 4th quarter valued at $33,000. Finally, Headlands Technologies LLC increased its position in shares of Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after buying an additional 96 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 8,705 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the transaction, the chief executive officer owned 80,773 shares of the company’s stock, valued at $22,613,209.08. This represents a 9.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brian J. Caveney sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares of the company’s stock, valued at $8,619,935.17. This represents a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 in the last ninety days. Corporate insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

LH has been the topic of several recent analyst reports. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. JPMorgan Chase & Co. raised their price target on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Piper Sandler lifted their price objective on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $304.82.

Labcorp Trading Down 1.4%

LH opened at $264.52 on Friday. The stock has a market capitalization of $21.80 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.83 and a beta of 1.01. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $293.72. The firm’s fifty day simple moving average is $274.20 and its 200 day simple moving average is $269.23. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last announced its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. During the same period in the prior year, the business earned $3.45 EPS. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, research analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Friday, February 27th were issued a dividend of $0.72 per share. The ex-dividend date was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.